JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 166 filers reported holding JUNO THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.25 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,802,000 | +0.9% | 70,649 | +14.2% | 0.01% | -7.7% |
| Q3 2017 | $2,776,000 | +82.8% | 61,877 | +21.7% | 0.01% | +62.5% |
| Q2 2017 | $1,519,000 | +42.6% | 50,827 | +5.9% | 0.01% | +33.3% |
| Q1 2017 | $1,065,000 | +311.2% | 48,016 | +248.8% | 0.01% | +200.0% |
| Q4 2016 | $259,000 | -79.4% | 13,766 | -67.2% | 0.00% | -75.0% |
| Q3 2016 | $1,259,000 | +10.1% | 41,966 | +41.1% | 0.01% | 0.0% |
| Q2 2016 | $1,143,000 | +4.0% | 29,740 | +3.1% | 0.01% | -11.1% |
| Q1 2016 | $1,099,000 | -29.4% | 28,840 | -18.5% | 0.01% | -30.8% |
| Q4 2015 | $1,556,000 | +25.0% | 35,395 | +15.7% | 0.01% | +18.2% |
| Q3 2015 | $1,245,000 | +1560.0% | 30,595 | +2367.3% | 0.01% | +1000.0% |
| Q1 2015 | $75,000 | -80.1% | 1,240 | -82.8% | 0.00% | -75.0% |
| Q4 2014 | $377,000 | – | 7,216 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |